Market revenue in 2023 | USD 6,085.9 million |
Market revenue in 2030 | USD 6,996.8 million |
Growth rate | 2% (CAGR from 2023 to 2030) |
Largest segment | Pneumococcal conjugate vaccine |
Fastest growing segment | Pneumococcal Conjugate Vaccine |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine |
Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Walvax Biotechnology, Beijing Minhai Biotechnology Co. |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pneumococcal vaccine market will help companies and investors design strategic landscapes.
Pneumococcal conjugate vaccine was the largest segment with a revenue share of 93.14% in 2023. Horizon Databook has segmented the North America pneumococcal vaccine market based on pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine covering the revenue growth of each sub-segment from 2018 to 2030.
In the North America pneumococcal vaccine market, the scenario is characterized by a growing awareness of the importance of vaccination in preventing pneumococcal diseases. Government health agencies and organizations are actively promoting vaccination campaigns to combat pneumococcal infections, driving market demand.
In addition, the presence of leading pharmaceutical companies, such as Pfizer Inc. and Merck & Co., Inc., competing to develop and market advanced pneumococcal vaccines intensifies competition in the market.
The market is also influenced by factors such as disease prevalence, public health initiatives, and regulatory frameworks governing vaccine approval and distribution. As the market continues to evolve, collaboration between healthcare stakeholders and sustained investment in research and development will play pivotal roles in shaping the future landscape of the North America pneumococcal vaccine market.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America pneumococcal vaccine market, including forecasts for subscribers. This continent databook contains high-level insights into North America pneumococcal vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account